Dova Pharmaceuticals, Inc.
SEC CIK 1685071 · DOVA · last insider filing 2019-11-15
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Jeffs Roger | Director | filed 2017 - 2019 |
| Wysenski Nancy | Director | filed 2018 - 2019 |
| Novak Alfred J | Director | filed 2017 - 2019 |
| Manning Paul B | Director | filed 2017 - 2019 |
| Goldman Steven M. | Director | filed 2017 - 2019 |
| Zaccardelli David | Director · President & CEO | filed 2018 - 2019 |
| Stalfort Sean | Director | filed 2017 - 2019 |
| Sapir Alex | Director · President & CEO | filed 2017 - 2018 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Allen LEE F MD PhD | Chief Medical Officer | filed 2017 - 2019 |
| Hahn Mark W | Chief Financial Officer | filed 2018 - 2019 |
| Laliberte Kevin | Sr. VP, Product Development | filed 2017 - 2019 |
| Hoitt Jason | Chief Commercial Officer | filed 2018 - 2019 |
| Blankenship Douglas | Chief Financial Officer | filed 2017 - 2017 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.